23andMe and Celmatix Collaborate to Improve Infertility Outcomes

Companies Join Forces to Validate and Discover Genetic Biomarkers
That May Redefine How Infertility is Diagnosed and Treated

NEW YORK–(BUSINESS WIRE)–Celmatix,
the only personalized medicine company focused specifically on fertility
and women’s health, and 23andMe,
Inc.
, the leading personal genetics company, announced a
collaboration today aimed at improving infertility outcomes. This
collaboration will accelerate the launch of Celmatix’s tests, which will
aim to provide physicians with a comprehensive genetic lens on
infertility. This will also enable the development of early screening
tests which will help OBGYNs identify women who are at risk for
premature decline of their ovarian function, which has both infertility
and broader health implications.

According to the CDC,
one out of eight couples in the US struggles to conceive. Today, there
are no comprehensive genetic tests available to guide the diagnosis and
treatment of infertility in women or men.

“The scale of the genetic data that 23andMe has amassed is unprecedented
for the field of reproductive medicine,” said Celmatix founder and CEO,
Piraye Yurttas Beim, Ph.D. “Celmatix has worked for six years in
partnership with the top fertility centers in the world to vet,
validate, and discover novel genetic biomarkers that will dramatically
impact the diagnosis and treatment of infertility. This collaboration
allows us to further accelerate this work with the amazing dedication of
the 23andMe research community. Together, we will be able to help more
people who are struggling to conceive, have a baby sooner.”

The collaboration will combine Celmatix’s discovery and annotation of
more than 5,200 genetic biomarkers related to fertility potential in
humans and 23andMe’s robust genetic database and research community.

“Fertility and women’s health have always been important to 23andMe and
our research mission,” said Emily Drabant Conley, Ph.D., vice president
of business development at 23andMe. “We chose Celmatix as our partner
for fertility research because they are the leader in the field
of personalized reproductive medicine. Through their big data platform
and comprehensive clinic network they have amassed a deep clinical
database on infertility treatments – combining that platform with
23andMe’s massive genetic database will create a uniquely powerful
engine to fuel discoveries on the genetics of infertility.
We believe Celmatix’s vision to provide women with genetic information
that can inform proactive fertility management will ultimately have a
meaningful impact on infertility outcomes.”

About Celmatix

Celmatix is a personalized medicine company that uses big data and
predictive analytics to help individuals who are struggling to have a
baby make informed decisions. Founded in 2009 and based in New York
City, Celmatix is disrupting the way women approach their lifelong
fertility journey by empowering them through science and technology. The
company’s digital platform, Polaris, is in use at top fertility clinics
across the country, helping them better leverage their data to optimize
the patient experience and reach outcomes more efficiently. Celmatix
also has an active research and development program dedicated to
decoding the genetic basis of fertility potential. For more information,
visit www.celmatix.com.

About 23andMe

23andMe, Inc. is the leading personal genetics company. Founded in 2006,
the mission of the company is to help people access, understand and
benefit from the human genome. 23andMe has over one million customers
worldwide with over 80 percent consented to participate in research.
23andMe, Inc. is located in Mountain View, CA. More information is
available at www.23andMe.com.

Contacts

Brew Media
Michelle Kim, 310-464-6344
mkim@brewpr.com